An automated pheochromocytoma and paraganglioma lesion segmentation AI-model at whole-body 68Ga- DOTATATE PET/CT.
Fahmida Haque, Jorge A Carrasquillo, Evrim B Turkbey...
https://pubmed.ncbi.nlm.nih.gov/39500789/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-10-16
56
Participants Needed
1
Research Sites
26 weeks
Total Duration
Researchers are investigating a rare type of tumor called neuroendocrine tumors NETs, which can arise in the gastrointestinal tract and pancreas. This study focuses on patients with inoperable NETs that express somatostatin receptors. The goal is to evaluate whether a combination of two drugs, Lutathera and Olaparib, can be safely given together and whether this treatment can shrink these tumors. The study is a phase III clinical trial conducted to assess safety, tolerability, and effectiveness. Participants will receive Lutathera intravenously every 8 weeks for a total of 4 cycles. Each cycle includes oral Olaparib taken twice daily for 4 weeks, starting 2 days before the Lutathera infusion. An amino acid infusion is also administered to protect the kidneys during treatment. Patients will be monitored closely with physical exams, blood and urine tests, heart function tests, and imaging scans including PETCT scans using radioactive tracers. The study includes dose escalation of Olaparib in phase I to find the maximum tolerated dose, followed by phase II treatment at that dose. Throughout the study, participants will attend regular clinic visits for evaluation and toxicity assessments, including follow-up visits 4 weeks after treatment ends, then every 12 weeks for 3 years, and yearly phone calls thereafter. Researchers will measure outcomes such as maximum tolerated dose, tumor response rates, progression-free survival, and overall survival. Participants will also complete questionnaires about their well-being and function to help assess treatment impact and safety over time.
CONDITIONS
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
J
Joy H Zou, R.N.
F
Frank I Lin, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Combination PRRT + Olaparib | Standard PRRT (Lu‑177‑DOTATATE) |
|---|---|---|
| What it is | A sequential dose‑escalation phase 1/2 trial combining Lu‑177‑DOTATATE infusions every ~8 weeks for 4 cycles plus daily Olaparib starting 2 days before first infusion through 4 weeks after last infusion | Lu‑177‑DOTATATE alone given approximately every 8 weeks for four infusions is an established peptide receptor radionuclide therapy (PRRT) for somatostatin receptor‑positive GEP‑NETs |
| Role in trial | Investigational therapy evaluated in two dosing cohorts (dose‑escalation and fixed‑dose) | Not part of the trial design; serves as external benchmark for clinical context |
| Primary use | To evaluate safety, tolerability, and preliminary efficacy of combining Olaparib with PRRT in inoperable GEP‑NETs | Used for treating progressive somatostatin receptor‑positive GEP‑NETs after progression on somatostatin analogues |
| How it is administered | Lu‑177‑DOTATATE administered IV every ~8 weeks for 4 cycles; Olaparib taken orally twice daily starting 2 days before first infusion until ~4 weeks after last infusion | Lu‑177‑DOTATATE administered IV every 8 weeks ×4 doses per FDA prescribing information |
| Evidence status | Early results indicate combination is feasible with manageable toxicity; efficacy still under investigation | PRRT with Lu‑177‑DOTATATE has established efficacy in improving progression‑free survival and tumor control in somatostatin receptor‑positive GEP‑NETs |
| Important risks | Potential for increased bone marrow suppression (e.g., thrombocytopenia), fatigue, nausea, and renal or hepatic toxicity; safety profile under evaluation | Known risks include myelosuppression, renal toxicity, hepatotoxicity, infusion reactions, and secondary marrow disorders |
| Important limitations | Early‑phase trial with small patient numbers; efficacy unconfirmed and optimal dosing not yet established | Does not address resistance mechanisms or improve outcomes beyond established progression‑free survival benefits |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 32 weeks (4 cycles, each 8 weeks)
Participants receive Lu-177-DOTATATE via intravenous infusion every 8 weeks for 4 cycles along with oral Olaparib taken twice daily for 4 weeks of each cycle. An amino acid infusion is also given to protect kidney function during treatments.
Clinic visits every 4 weeks and phone toxicity assessments after each infusion
Duration - Up to 3 years and beyond
Participants have follow-up visits every 12 weeks for 3 years, then yearly phone calls to monitor disease status and overall health after treatment ends.
Visits every 12 weeks for 3 years, then yearly phone calls
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Fahmida Haque, Jorge A Carrasquillo, Evrim B Turkbey...
https://pubmed.ncbi.nlm.nih.gov/39500789/National Cancer Institute (NCI)
Lead Sponsor